Şunu aradınız:: cattle (Fince - İngilizce)

marky cattle association – marchigiana
marky cattle association — marchigiana

cattle vaccine against ibr (qj57da)
cattle vaccine against ibr (qj57da)

senopol cattle breeders association – senopol
senopol cattle breeders association — senopol

dairy cattle clinical sub-clinical mastitis
· dairy cattle · clinical sub-clinical mastitis

american highland cattle association – scotch highland
american highland cattle association — scotch highland

cattle & pigs antibacterial for systemic use (qj01ma)
cattle & pigs antibacterial for systemic use (qj01ma)

ayrshire breeders' association of canada – ayrshire cattle
ayrshire breeders' association of canada — ayrshire cattle c/o yvon rioux

a) cattle b) adjunctive therapy in acute respiratory infection
therapy in acute respiratory infection

a) dairy cattle, ovine, rabbits b) 08. 07. 98
a) dairy cattle, ovine, rabbits

canadian blonde d’aquitaine association - blonde d’aquitaine cattle
canadian blonde d’aquitaine association — blonde d’aquitaine cattle

canadian meuse-rhine-ijssel association - meuse-rhine-ijssel cattle
canadian meuse-rhine-ijssel association — meuse-rhine-ijssel cattle

asiakirjan nimi antimicrobials for general use in target animal species summary of product characteristics for antimicrobial products efficacy requirements for ectoparasiticides for cattle fluid therapy
biopharmaceutical characterisation and bioavailability/ bioequivalence of herbal drugs/preparations position paper on the risk associated with the use of herbal products containing estragole position paper on the risk associated with the use of herbal products containing methyleugenol position paper on the risk associated with the use of herbal

cvmp: n tehokkuustyöryhmäasiakirjan nimi antimicrobials for general use in target animal species summary of product characteristics for antimicrobial products efficacy requirements for ectoparasiticides for cattle fluid therapy
core-data on primulae radix 35 emea work programme 2003chapter 1 emea in the european systemcvmp efficacy working party document title antimicrobials for general use in target animal species summary of product characteristics for antimicrobial products efficacy requirements for ectoparasiticides for cattle fluid therapy

butafosfan dairy cattle - 19. 01. 2000 (extension) - 19. 04. 2000 - 90 days - 0
- 19.01.2000 - 19.04.2000 - 90 days -0

emea/mb/050 vuosikertomus 2000 sivu 83/85 cvmp: n tehokkuustyöryhmä viitenumero ohje tilanne conduct of pharmacokinetic studies in emea/cvmp/133/99 hyväksytty maaliskuussa 2000 animals conduct of efficacy studies for emea/cvmp/344/99 hyväksytty maaliskuussa 2000 intramammary products for use in cattle testing and evaluation of the efficacy of antiparasitic substances for the treatment emea/cvmp/005/00 hyväksytty marraskuussa 2000 and prevention of tick and flea infestation in cats and dogs the conduct of bioequivalence studies for toimitettu lausuntoa varten emea/cvmp/016/00 veterinary medicinal products tammikuussa 2000 efficacy of anthelmintics:
guidelines/status conduct of pharmacokinetic studies in animals adopted march 2000 conduct of efficacy studies for intramammary products for use in cattle adopted march 2000 testing and evaluation of the efficacy of antiparasitic substances for the treatment and prevention of tick and flea infestation in cats and dogs adopted november 2000 the conduct of bioequivalence studies for veterinary medicinal products released for consultation january 2000 efficacy of anthelmintics: